Insulin-like growth factor-binding proteins and bone metabolism

Current understanding of bone metabolism includes the role of growth factors like insulin-like growth factors (IGFs). However, the influence of IGF-binding proteins (IGFBPs) remains unclear. Prior research has shown that IGFBPs modulate IGF activity, but their exact contributions to bone health are not fully mapped. No prior work had resolved how IGFBPs function independently of IGFs in bone. This uncertainty drives the need to clarify IGFBP roles. Studies have identified both activating and inhibitory effects of IGFBPs. The complexity of IGFBP function depends on context and modifications. This gap motivated recent investigations into IGFBP-2, IGFBP-4, and IGFBP-5. Understanding these proteins may improve clinical approaches to bone diseases.

This review aims to clarify the roles of IGFBP-2, IGFBP-4, and IGFBP-5 in bone metabolism. The specific problem is the lack of consensus on how these proteins influence bone cells. The motivation stems from conflicting evidence on IGFBP effects. The authors propose to synthesize findings from recent studies. They focus on cell culture, rodent models, and clinical data. The goal is to determine whether IGFBPs act primarily through IGFs or independently. The study also seeks to identify patterns in IGFBP behavior across species. This approach may help distinguish regulatory mechanisms in bone.

The authors reviewed recent literature on IGFBP-2, IGFBP-4, and IGFBP-5 in bone metabolism. They analyzed findings from cell culture experiments, rodent studies, and clinical trials. The review approach included comparing results across different models. The authors focused on local effects of these proteins in bone tissue. They examined how IGFBPs interact with IGFs and other signaling pathways. The analysis considered posttranslational modifications and their impact. The authors also evaluated IGF-independent functions of IGFBPs. This synthesis aimed to identify consistent patterns in IGFBP behavior.

IGFBP-2 showed both stimulatory and inhibitory effects in bone cell cultures. In rodent models, IGFBP-2 increased bone formation in some cases. Clinical studies suggest IGFBP-2 may influence bone density in humans. IGFBP-4 was found to inhibit IGF activity in osteoblasts. However, in some contexts, IGFBP-4 enhanced bone resorption. IGFBP-5 appeared to support osteoblast differentiation in vitro. Rodent studies showed IGFBP-5 could increase bone mass. Clinical data suggest IGFBP-5 levels correlate with bone turnover markers.

The authors propose that IGFBPs modulate bone metabolism through multiple mechanisms. They suggest that IGFBP-2, IGFBP-4, and IGFBP-5 have distinct but overlapping roles. The findings indicate that IGFBPs can act both with and without IGFs. The authors emphasize the context-dependent nature of IGFBP effects. They propose that posttranslational modifications influence IGFBP function. The review highlights the need for further studies on IGFBP-independent pathways. The authors suggest that IGFBPs may serve as therapeutic targets. These conclusions are based on synthesized evidence from recent studies.